Correction
12 February 2020
Biomarkers for Hepatobiliary Cancers
Jean‐Charles Nault, Augusto Villanueva – 11 February 2020 – The clinical management of primary liver cancers such as hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) has significantly changed in the last 3 years. The introduction of systemic therapies, including immune‐based therapies and biomarker‐driven therapies, has significantly improved survival, particularly in patients at advanced stages of disease. Survival is still poor, and projections from the World Health Organization underscore the need to improve outcomes in these patients.
Reply
Lai Wei, Pik Eu Jason Chang, Quentin M. Anstee – 11 February 2020
Deletion of Protein Kinase D3 Promotes Liver Fibrosis in Mice
Shuya Zhang, Huan Liu, Meimei Yin, Xiuying Pei, Angelika Hausser, Eri Ishikawa, Sho Yamasaki, Zheng Gen Jin – 11 February 2020
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD
James M. Paik, Pegah Golabi, Youssef Younossi, Alita Mishra, Zobair M. Younossi – 11 February 2020
Letter to the Editor: Quantitative Histological Assessment in Nonalcoholic Fatty Liver Disease
Samer Gawrieh, David E. Kleiner, Naga Chalasani, Scott Vanderbeck – 11 February 2020
Masthead
10 February 2020
Instructions to Authors
10 February 2020
Hepatology Highlights
Alyson Kaplan, Russell Rosenblatt, Nicholas W. Russo, Robert S. Brown, Joseph F. Pisa, Petra Hirsova, Robert E. Schwartz, Enis Kostallari, Nidhi Jalan‐Sakrikar, Rajab Idriss, Hirsh Trivedi, Daryl T.Y. Lau, Amaia Navarro‐Corcuera – 10 February 2020
Notices
10 February 2020